Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival

Full text
Author(s):
Carrara, Guilherme Freire Angotti [1] ; Evangelista, Adriane Feijo [1, 2] ; Scapulatempo-Neto, Cristovam [1, 3] ; Abrahao-Machado, Lucas Faria [3] ; Morini, Mariana Andozia [3] ; Kerr, Ligia Maria [3] ; Folgueira, Maria Aparecida Azevedo Koike [4] ; da Costa Vieira, Rene Aloisio [1, 5]
Total Authors: 8
Affiliation:
[1] Hosp Canc Barretos, Programa Posgrad Oncol, Rua Antenor Duarte Villela 1331, BR-14784400 Barretos, SP - Brazil
[2] Hosp Canc Barretos, Ctr Pesquisa Mol Oncol, Barretos - Brazil
[3] Hosp Canc Barretos, Dept Patol, Barretos - Brazil
[4] Univ Sao Paulo, Dept Radiol & Oncol, Programa Posgrad Oncol, Fac Med, FMUSP, Sao Paulo - Brazil
[5] UNESP, Fac Med Botucatu, Programa Posgrad Ginecol Obstet & Mastol, Botucatu, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: BREAST CANCER; v. 28, n. 2, p. 307-320, MAR 2021.
Web of Science Citations: 0
Abstract

Background Non-metastatic locally advanced breast carcinoma (LABC) treatment involves neoadjuvant chemotherapy (NCT). We evaluated the association of clinical-pathological data and immunoexpression of hormone receptors, HER2 and Ki67, and new biomarkers, RPL37A, MTSS1 and HTRA1, with pathological complete response (PCR) or tumour resistance (stable disease or disease progression), disease-free survival (DFS) and cancer-specific survival (CSS). Methods This is a retrospective study of 333 patients with LABC who underwent NCT. Expression of MTSS1, RPL37A and HTRA1/PRSS11 was evaluated by immunohistochemistry in TMA slides. Cutoff values were established for low and high tumour expression. ROC plotter evaluated response to NCT. Chi-square test for factors related to PCR, and Kaplan-Meier test and Cox model for factors related to DFS and CSS were prformed. Results The mean follow-up was 70.0 months and PCR rate was 15.6%. At 120 months, DFS rate was 32.5% and CSS rate was 67.1%. In multivariate analysis, there was an association between: (1) necrosis presence, intense inflammatory infiltrate, ER absence, HER2 molecular subtype and high RPL3A expression with increased odds of PCR; (2) lymph node involvement (LNI), high Ki67, low RPL37A and high HTRA1 expression with increased risk for NCT non-response; (3) LNI, high proliferation, necrosis absence, low RPL37A and high HTRA1 expression with increased recurrence risk; (4) advanced LNI, ER negative tumours, high HTRA1, low RPL37A expression and desmoplasia presence with higher risk of cancer death. Conclusion RPL37A is a potential biomarker for response to NCT and for prognosis. Additional studies evaluating HTRA1 and MTSS1 prognostic value are needed. (AU)

FAPESP's process: 12/19642-0 - Clinical and pathological factors related to complete patologic response and local recurrence in patients with locally advanced breast cancer, submitted to neoadjuvant chemotherapy
Grantee:René Aloisio da Costa Vieira
Support Opportunities: Regular Research Grants